A recent study focused on investigating the potential advantages of including fatty fish in the diet of individuals with impaired glucose metabolism or coronary heart disease. The study aimed to understand how different dietary choices, such as the consumption of Camelina sativa oil (CSO), fatty fish (FF), or lean fish (LF) affect membrane fluidity. The results of the study provided valuable insights into the impact of these dietary choices.
In the Fish trial, 33 participants with myocardial infarction or unstable ischemic heart attack were randomized into CSO, FF, LF, or control groups. Similarly, in the AlfaFish trial, 70 participants with impaired glucose intolerance were randomized into CSO, FF, LF, or control groups.
During the study, participants in the fatty fish group experienced a significant reduction in the lipophilic index, which is a measure of membrane fluidity, when compared to the control group in both experimental trials. On the other hand, no significant changes in membrane fluidity were observed in the lean fish or Camelina sativa oil groups. These findings indicate that adding fatty fish to one’s diet could be an effective strategy to lower the risk of cardiovascular disease by enhancing membrane fluidity.
In conclusion, this study shed light on the potential benefits of consuming fatty fish for individuals with impaired glucose metabolism or coronary heart disease. By investigating the effects of different dietary choices on membrane fluidity, the research revealed that fatty fish intake may lead to a significant decrease in the lipophilic index. Incorporating fatty fish into one’s diet may therefore serve as a beneficial approach to mitigate the risk of cardiovascular disease by improving membrane fluidity.
